513 related articles for article (PubMed ID: 28390900)
21. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
[TBL] [Abstract][Full Text] [Related]
22. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Kamath D; Iwakuma T; Bossmann SH
Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
[TBL] [Abstract][Full Text] [Related]
24. The interplay between mutant p53 and the mevalonate pathway.
Parrales A; Thoenen E; Iwakuma T
Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
[TBL] [Abstract][Full Text] [Related]
25. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.
Brázdová M; Navrátilová L; Tichý V; Němcová K; Lexa M; Hrstka R; Pečinka P; Adámik M; Vojtesek B; Paleček E; Deppert W; Fojta M
PLoS One; 2013; 8(3):e59567. PubMed ID: 23555710
[TBL] [Abstract][Full Text] [Related]
26. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.
Cooks T; Pateras IS; Jenkins LM; Patel KM; Robles AI; Morris J; Forshew T; Appella E; Gorgoulis VG; Harris CC
Nat Commun; 2018 Feb; 9(1):771. PubMed ID: 29472616
[TBL] [Abstract][Full Text] [Related]
28. Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome.
Zhang Y; Hu Y; Fang JY; Xu J
Oncotarget; 2016 Mar; 7(10):11056-66. PubMed ID: 26840456
[TBL] [Abstract][Full Text] [Related]
29. SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Gomes AS; Ramos H; Gomes S; Loureiro JB; Soares J; Barcherini V; Monti P; Fronza G; Oliveira C; Domingues L; Bastos M; Dourado DFAR; Carvalho AL; Romão MJ; Pinheiro B; Marcelo F; Carvalho A; Santos MMM; Saraiva L
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129440. PubMed ID: 31536751
[TBL] [Abstract][Full Text] [Related]
30. A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis.
Yue X; Zhao Y; Huang G; Li J; Zhu J; Feng Z; Hu W
Cell Discov; 2016; 2():16039. PubMed ID: 27807478
[TBL] [Abstract][Full Text] [Related]
31. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
33. [Advances on mutant p53 research].
Li DH; Zhang LQ; He FC
Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
[TBL] [Abstract][Full Text] [Related]
34. Regulation of p53 and Cancer Signaling by Heat Shock Protein 40/J-Domain Protein Family Members.
Kaida A; Iwakuma T
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948322
[TBL] [Abstract][Full Text] [Related]
35. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
36. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
Schulz-Heddergott R; Moll UM
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
[TBL] [Abstract][Full Text] [Related]
37. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
39. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.
Tal P; Eizenberger S; Cohen E; Goldfinger N; Pietrokovski S; Oren M; Rotter V
Oncotarget; 2016 Mar; 7(11):11817-37. PubMed ID: 26943582
[TBL] [Abstract][Full Text] [Related]
40. Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion.
Zhang S; Wang C; Ma B; Xu M; Xu S; Liu J; Tian Y; Fu Y; Luo Y
Cell Rep; 2020 Jul; 32(1):107879. PubMed ID: 32640214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
